CERO THERAPEUTICS HOLDINGS I (CERO) Stock News

USA - NASDAQ:CERO - US71902K4022 - Common Stock

0.0951 USD

-1.69 (-94.69%)

Last: 10/30/2025, 8:00:00 PM

0.12 USD

+0.02 (+26.18%)

After Hours: 10/30/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CERO Latest News, Press Relases and Analysis

All

Press Releases

12 days ago - By: Chartmill - Mentions: BTU TGE AMTD FMFC ...

News Image

Stay updated with the stocks that are on the move in today's after-hours session.

13 days ago - By: Chartmill - Mentions: ATEC SPSC ARDX CRBP ...

News Image

Top movers in Thursday's after hours session

7 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

8 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

9 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Listing on OTC Markets

13 days ago - By: Benzinga - Mentions: HBIO IART EBS GH ...

12 Health Care Stocks Moving In Thursday's Intraday Session

14 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

14 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

22 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

22 days ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

a month ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

2 months ago - By: Benzinga - Mentions: SMMT RENB

Top 3 Health Care Stocks You'll Regret Missing In Q3

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

2 months ago - By: Stocktwits

News Image

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

2 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

3 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

3 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

5 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

5 months ago - By: CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236